

April 08, 2021

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
BSE Scrip Code: 531349

**Sub.: Clarification on news item appearing in “economictimes.indiatimes.com”
captioned “Panacea in talks with Bharat Biotech to make Covaxin”**

Ref.: Your e-mail dated April 08, 2021

Dear Sir/Madam,

With reference to the captioned subject, we would like to state as under:

1. As a policy, the Company does not comment on media speculation and rumours and cannot confirm or deny any transaction which may or may not be in the works. Our Company evaluates various opportunities on an ongoing basis.
2. We have made and will continue to make necessary disclosures in compliance with our obligations under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

You are requested to take the same on records.

Thanking you,

Sincerely yours,

For **Panacea Biotec Ltd.**



Vinod Goel
Group CFO and Head Legal
& Company Secretary

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com